

Initial Outcomes from NACMI

The North American COVID-19 STEMI Registry



Timothy D. Henry, MD

Medical Director, The Carl and Edyth Lindner Center for Research and Education

The Christ Hospital , Cincinnati, OH

Santiago Garcia, MD, Cindy L. Grines MD, Laura J. Davidson MD, Keshav Nayak MD, Jacqueline Saw MD, Akshay Bagai MD, Ross Garberich MS, Christian Schmidt MS, Hung Q. Ly MD, SM, Jay Giri MD, Ron Waksman MD, Raj Patel MD, Lindsey Cilia MD, Scott Sharkey MD, David A. Wood MD, Frederick G. Welt MD, Ehtisham Mahmud MD, Payam Dehghani MD

Disclosure Statement of Financial Interest

I, **Timothy D. Henry**, have nothing to disclose.

Cardiovascular Manifestations of COVID-19

- Patients with cardiovascular disease have increased risk of mortality with COVID-19
- 15-28% of COVID+ patients admitted to the hospital have elevated Troponin
- 28-45% reduction in STEMI activation and cardiovascular admissions
- COVID+ patients with ST-Segment elevation represent a particularly unique and challenging population

STEMI in COVID-19: Published Data

- 5 publications with a total of 174 COVID+ patients with ST-Elevation (Range 11-78)
- Key findings:
 - More frequent in-hospital presentations
 - More thrombotic lesions and pathologic reports of “microthrombi”
 - More frequent “no-culprit” (range 5-55%)
 - Higher mortality (range 12-72%)
 - Considerable controversy regarding appropriate management
 - SCAI/ACC/ACEP Guidelines



Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, Mattu A, Kirtane AJ, Jauhar R, Meraj P, Rokos IC, Rumsfeld JS, Henry TD. Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A position statement from the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). J Am Coll Cardiol. 2020 Sep 15;76(11):1375-1384.

North American COVID Myocardial Infarction Registry

Goals:

- To create a multi-center database of COVID+ or persons under investigation (PUI) who present with ST-Segment Elevation or new left bundle branch block (LBBB) on ECG
- To *compare* the demographics, clinical findings, outcomes and management strategies of COVID+ Pts to a propensity matched historical control of STEMI activation patients from the *Midwest STEMI Consortium*
- To develop *data-driven treatment plans*, guidelines and diagnostic acumen regarding these unique patients

NACMI: A Unique Collaboration




North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications

Am Heart J. 2020 Sep;227:11-18.


Inclusion and Exclusion Criteria

- 1) COVID+ or PUI
- 2) ST-segment elevation or new-onset LBBB on 12-lead ECG
- 3) >18 years of age
- 4) Include a **clinical correlate of myocardial ischemia** (e.g., chest or abdominal discomfort, dyspnea, cardiac arrest, shock, mechanical ventilation)
- No exclusion criteria

Pathways for enrollment into NACMI



Methods: NACMI Registry



Primary Objective: Create a multi-center database for Groups 1&2 presenting with ST segment elevation or new LBBB

Secondary Objective:

1. Compare the demographics, clinical findings, outcomes, and management of Groups 1&2
2. Compare the demographics, clinical findings, outcomes, and management of Groups 1&3

Primary Outcome: In-hospital MACE

Secondary Outcome:

1. Etiologies of ST elevation
2. 1-year MACE
3. Individual components of MACE
4. ECG and angiographic characteristics
5. Analysis of groups of interest**

NACMI Sites

Total Active Sites*: 64
(11 in progress)



Top Overall sites, USA

Mercy Health St. Vincent = 62
Community Medical = 56
Southcoast Health = 55
Massachusetts General Hospital = 44
Holy Cross Hospital = 32
Northside Hospital = 32
University of Chicago = 21
DMC Harper University Hospital = 20
Mayo Clinic Jacksonville = 16
Northwestern University = 12

Top COVID 19 + sites, USA

Northside Hospital = 24
DMC Harper University Hospital = 10
Medstar Health = 9
Northwestern University = 9
Massachusetts General Hospital = 8
Ochsner Medical Center = 8
Scripps Health = 7
University of Arizona = 7
New York Presbyterian = 6
Cedars Sinai = 5
Cook County Hospital = 5
Southcoast Health = 5

Total patients enrolled*: 594
(171 COVID+, 423 PUI)



Top overall sites, Canada

Vancouver Coastal = 34
Royal University Hospital = 30
Sunnybrook Research = 20
Regina General Hospital = 14
University of Ottawa = 6
Nova Scotia Health = 4
Windsor Regional Hospital = 3
Horizon Health Network = 2
St. Mary's General Hospital = 2
William Osler Health = 2

Top COVID 19 + sites, Canada

Sunnybrook Research = 3
Windsor Regional Hospital = 3
Royal University Hospital = 2
Lawson Health Research = 1
St. Mary's General Hospital = 1
University of Ottawa = 1
Vancouver Coastal = 1
William Osler Health = 1

*As of 10/4/20

Results: Baseline Characteristics

	COVID + (n=171)	PUI (n=423)	p-value	Propensity- Matched MSC	p- value
Male, n (%)	120 (70)	311 (74)	0.408	253 (74)	0.362
Age group, n (%)			0.351		1.000
18-55	39 (23)	121 (29)		78 (23)	
56-65	52 (30)	135 (32)		104 (30)	
66-75	48 (28)	88 (21)		96 (28)	
76-85	25 (15)	61 (14)		50 (15)	
>85	7 (4)	18 (4)		14 (4)	
Race, n (%)			<0.001		<0.001
Caucasian	56 (33)	301 (74)		316 (93)	
African American	45 (27)	44 (11)		14 (4)	
Asian	12 (7)	23 (6)		4 (1)	
Hispanic	41 (24)	23 (6)		2 (1)	
Indigenous	4 (2)	7 (2)		3 (1)	
Other	11 (7)	7 (2)			
Diabetes, n (%)	73 (44)	134 (33)	0.015	69 (20)	<0.001
Hypertension, n (%)	121 (73)	303 (74)	0.734	209 (61)	0.010
Dyslipidemia, n (%)	77 (48)	241 (61)	0.004	187 (55)	0.117

Results: Clinical Presentation

	COVID + (n=171)	PUI (n=423)	p-value	Propensity- Matched MSC	p- value
Cardiac Arrest Pre-PCI, n (%)	17 (12)	70 (17)	0.128	37 (11)	0.771
Card Shock Pre-PCI, n (%)	29 (20)	56 (14)	0.074	14 (5)	<0.001
<i>Ejection Fraction</i>	45 (35, 55)	45 (35, 52.5)	0.948	50 (40, 58)	0.009
Chest X-Ray				NA	NA
<i>Infiltrates</i>	84 (49)	71 (17)	<0.001		
Pleural effusion	11 (6)	29 (7)	0.852		
Cardiomegaly	15 (9)	23 (5)	0.133		
Symptoms, n (%)				NA	NA
<i>Dyspnea</i>	99 (58)	162 (38)	<0.001		
Chest Pain	90 (53)	329 (78)	<0.001		
Syncope	1 (1)	22 (5)	0.008		
In-hospital STEMI	10 (6)	7 (2)	0.005	NA	NA

Results: Treatment Strategies

	COVID + (n=171)	PUI (n=423)	p-value	Propensity- Matched MSC	p- value
No Angiography, n (%)	33 (21)	19 (5)	<0.001	0%	<0.001


Reperfusion Strategy in Patients Undergoing Angiography (p<0.001)

Thrombolytics	7 (6)	9 (2)	0.069	9 (3)	0.130
<i>Primary PCI</i>	90 (71)	313 (80)	0.030	277 (81)	0.015
Facilitated/Rescue PCI	3 (2)	8 (2)	0.735	NA	NA
<i>Medical Tx</i>	25 (20)	45 (12)	0.019	34 (10)	0.005
CABG	2 (2)	16 (4)	0.265	10 (3)	0.402
Door-to-balloon time	80 (54, 127)	78 (55, 115)	0.773	86 (64, 112)	0.902

Culprit Artery in Patients Undergoing Angiography (p=NS)

LMCA	3 (2)	12 (3)	1.000	2 (1)	0.129
LAD/Diagonal	50 (40)	180 (46)	0.237	106 (32)	0.105
LCx/OM/PDA	13 (10)	67 (17)	0.070	46 (14)	0.326
RCA/PDA	49 (39)	152 (39)	0.948	120 (36)	0.546
Graft	0 (0)	5 (1)	0.343	9 (3)	0.122
Ramus	0 (0)	5 (1)	0.343		

Clinical Outcomes



Summary

Compared to both PUI and propensity matched controls;

- ST-Elevation occurred more frequently in Blacks, Hispanics and Diabetics
- COVID+ patients with ST-Elevation were more likely to present with cardiogenic shock (but not cardiac arrest) with lower LVEF, more atypical symptoms and slightly higher in-hospital presentation
- COVID+ patients with ST-Elevation were more likely to not receive angiography (21%) and to receive medical therapy but still 71% received PPCI and lytics were uncommon.
- No differences in culprit vessel and similar door to balloon times
- COVID+ patients with ST-Elevation had higher in-hospital mortality and in-hospital stroke with longer length of stay

Conclusion

- NACMI represents a successful collaboration of North American Interventional Cardiologists (SCAI/CAIC/ACC Interventional Council)
- COVID+ patients with ST-Elevation represent a unique and high-risk patient population
- Primary PCI is preferable (and feasible) in COVID+ patients with D2B times similar to PUI or COVID– patients, supporting current SCAI/ACC/AHA recommendations

Future Directions

- Ongoing enrollment – and expansion
 - ┆ Targeted high COVID prevalence sites/Mexico/South America
- Angiographic and EKG core labs
- Selected topics of interest
 - ┆ Ethnic differences
 - ┆ Regional and Country Differences
 - ┆ Time to Treatment/Transfer/In-Hospital/No Culprit
 - ┆ Changes over time
 - ┆ Long term outcomes

